1. Normal imaging findings after ascending aorta prosthesis implantation on 18 F-Fluorodeoxyglucose Positron Emission Tomography with computed tomography.
- Author
-
Wahadat AR, Tanis W, Mulders TA, Graven LH, Bekker MWA, Bekkers JA, Roos-Hesselink JW, and Budde RPJ
- Subjects
- Humans, Male, Middle Aged, Aged, Female, Positron Emission Tomography Computed Tomography methods, Aorta, Thoracic, Radiopharmaceuticals, Positron-Emission Tomography, Fluorodeoxyglucose F18, Heart Valve Prosthesis Implantation
- Abstract
Background: To diagnose abnormal
18 F-Fluorodeoxyglucose (18 F-FDG) uptake in suspected endocarditis after aortic root and/or ascending aorta prosthesis (ARAP) implantation, it is important to first establish the normal periprosthetic uptake on positron emission tomography with computed tomography (PET/CT)., Methods: Patients with uncomplicated ARAP implantation were prospectively included and underwent18 F-FDG-PET/CT at either 12 (± 2) weeks (group 1) or 52 (± 8) weeks (group 2) after procedure. Uptake on three different locations of the prosthesis ("cranial anastomosis (CA)," "prosthetic heart valve (PHV)," "ascending aorta prosthesis (AAP)") was scored visually (none/low/intermediate/high) and quantitatively (maximum standardized uptake value (SUVmax ) and target-to-background ratio (SUVratio )., Results: In total, 20 patients (group 1: n = 10, group 2: n = 10) (mean age 64±7 years, 70% male) were included. Both groups had similar visual uptake intensity for all measured areas (CA: mostly low-intermediate (16/20 (80%)), p = .17; PHV: low-intermediate (16/20 (80%)), p = .88; AAP: low-intermediate (19/20 (95%)), p = .48). SUVmax for CA was 5.6 [4.1-6.1] and 3.8 [3.1-5.9] (median [IQR], p = .19), and around PHV 5.0 [4.1-5.7] and 6.3 [4.6-7.1] (p = .11) for groups 1 and 2, respectively. SUVratio for CA was 2.8 [2.3-3.2] and 2.0 [1.7-2.6] (median [IQR], p = .07) and around PHV 2.5 [2.4-2.8] and 2.9 [2.3-3.5] (median [IQR], p = .26) for groups 1 and 2, respectively., Conclusion: No significant differences were observed between PET/CT findings at 3 months and 1 year after ARAP implantation, warranting caution in interpretation of PET/CT in the first year after implantation., (© 2021. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF